Table 1 Demographic, clinical, and histopathologic data for MPM patient cohort

From: V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

Characteristic

n = 319 (%)

Sex, male/female

237/82 (74/26)

Age (yr) at diagnosis, median (range)

64 (29–85)

Procedure

 

 Biopsy

21 (7)

 Pleurodesis/decortication

121 (38)

 Extrapleural pneumonectomy

177 (55)

Tumor histology

 

 Epithelioid

254 (80%)

 Biphasic

41 (13%)

 Sarcomatoid

24 (7%)

Pathologic stagea

 

 I

10 (3)

 II

75 (24)

 III

187 (60)

 IV

39 (13)

Overall survival (mo), median (range)

12 (0–246.7)

  1. aA subset that were not resected were staged clinically
  2. MPM malignant pleural mesothelioma, mo month, n number, yr year